CRWE, NSPH, ENTR, ABMD - CRWEPicks.com Stock Report! Crown Equity Holdings, Nanosphere, Entropic Communications, Abiomed
RSOL, NSPH, CRWE, HMST - CRWEWallStreet.com Stock News! Real Goods Solar, Nanosphere, Crown Equity Holdings, HomeStreet
Nanosphere, Inc Non Normal Trade in last session - NASDAQ:NSPH
Nanosphere, Inc (NASDAQ:NSPH) witnessed volume of 1.09 million shares during last trade however it holds an average trading capacity of 408,133 shares. NSPH last trade opened at $1.27 reached intraday low of $1.24 and went +5.60% up to close at $1.32.
Read Full Article and Disclaimer at :http://stockbling.com/7701/business-news/nanosphere-inc-non-normal-trade...
ABM, NSPH, JAZZ, - CRWESelect.com Stocks To Watch! ABM Industries, Nanosphere, Jazz Pharmaceuticals (Video Included Inside)
To View Video, Read the full article and the disclaimer visit URL http://crweselect.com/26308/stock-alerts/abm-nsph-jazz-crweselectcom-sto...
ABM Industries Inc. (NYSE:ABM)
(NSPH, ABM, JAZZ) PennyOmega.com Watch List for Tuesday Sept. 20, 2011
MRX, LBIX, NHPR.OB, IPAS, SNTA, NSPH, - CRWESelect.com Stock Report! Medicis Pharmaceutical Corp. (Video Included Inside!)
IIN, GRHU, NSPH, AVOT, CADE - Stock Update From DoubleInStocks.com!
LNWZ.OB, NANX, NSPH, NSSC, - League Now Holdings Acquired Pure Motion, Technologies, Molecular Diagnostics and Security Products
NSPH, HAFC, TXRH, CIA - Saturday Company Update From PennytoBuck.com - Nanosphere Inc, Hanmi Financial Corp, Texas Roadhouse,
Nanosphere, Inc., (Nasdaq:NSPH), which develops, manufactures, and markets advanced molecular diagnostics systems, will report its results for the third quarter of 2010 after the market closes on Wednesday, November 3, 2010.
NSPH will also hold a live investor conference call and webcast at 5:00 P.M., Eastern Time.
Molecular Insight Pharmaceuticals, Inc. (NASDAQ:MIPI) presented positive data from Phase 1 clinical studies comparing Trofex™ (123I-MIP-1072), its lead molecular imaging candidate for the diagnosis and monitoring of metastatic prostate cancer, and ProstaScint® (111In-capromab pendetide), an imaging radiopharmaceutical for the visualization of metastatic prostate cancer.